{"id":"preservative-free-tafluprost-0-0015","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Conjunctival hyperemia"},{"rate":"10-30","effect":"Eye irritation/discomfort"},{"rate":"5-15","effect":"Increased iris pigmentation"},{"rate":"5-15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-10","effect":"Periocular skin darkening"}]},"_chembl":{"chemblId":"CHEMBL1963683","moleculeType":"Small molecule","molecularWeight":"452.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tafluprost mimics the action of prostaglandin F by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional (uveoscleral) pathway, leading to decreased intraocular pressure. The preservative-free formulation reduces ocular surface irritation compared to preserved versions.","oneSentence":"Tafluprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:31.426Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT03822559","phase":"PHASE3","title":"A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2019-01-20","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":219},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT04654611","phase":"PHASE4","title":"Tafluprost Preservative Free Switch Study","status":"COMPLETED","sponsor":"Tun Hussein Onn National Eye Hospital","startDate":"2019-02-01","conditions":"Glaucoma, Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":28},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT02102750","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2014-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":17},{"nctId":"NCT01026831","phase":"PHASE3","title":"Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":643},{"nctId":"NCT03104621","phase":"PHASE4","title":"Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2013-03","conditions":"Primary Open-angle Glaucoma","enrollment":20},{"nctId":"NCT01369771","phase":"PHASE4","title":"The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma","status":"COMPLETED","sponsor":"FinnMedi Oy","startDate":"2010-08","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":30},{"nctId":"NCT01162603","phase":"PHASE4","title":"Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2011-03","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":40},{"nctId":"NCT01434888","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-09","conditions":"Healthy Volunteers","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"preservative free tafluprost 0.0015%","genericName":"preservative free tafluprost 0.0015%","companyName":"Tun Hussein Onn National Eye Hospital","companyId":"tun-hussein-onn-national-eye-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafluprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}